Conor McCafferty,Tengyi Cai,Delphine Borgel,Dominique Lasne,Sylvain Renolleau,Meryl Vedrenne-Cloquet,Damien Bonnet,Jemma Wu,Thiri Zaw,Atul Bhatnagar,Xiaomin Song,Suelyn Van Den Helm,Natasha Letunica,Chantal Attard,Vasiliki Karlaftis,Slavica Praporski,Vera Ignjatovic,Paul Monagle

Abstract:Abstract COVID-19 has infected more than 275 million worldwide (at the beginning of 2022). Children appear less susceptible to COVID-19 and present with milder symptoms. Cases of children with COVID-19 developing clinical features of Kawasaki-disease have been described. Here we utilise Mass Spectrometry proteomics to determine the plasma proteins expressed in healthy children pre-pandemic, children with multisystem inflammatory syndrome (MIS-C) and children with COVID-19 induced ARDS. Pathway analyses were performed to determine the affected pathways. 76 proteins are differentially expressed across the groups, with 85 and 52 proteins specific to MIS-C and COVID-19 ARDS, respectively. Complement and coagulation activation are implicated in these clinical phenotypes, however there was significant contribution of FcGR and BCR activation in MIS-C and scavenging of haem and retinoid metabolism in COVID-19 ARDS. We show global proteomic differences in MIS-C and COVID-ARDS, although both show complement and coagulation dysregulation. The results contribute to our understanding of MIS-C and COVID-19 ARDS in children.

Pathophysiological pathway differences in children who present with COVID-19 ARDS compared to COVID -19 induced MIS-C